Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Myocarditis and/or pericarditis risk after mRNA COVID-19 vaccination: A Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines
Natalia Abraham, Sarah Spruin, Tanya Rossi, et al.
Vaccine (2022) Vol. 40, Iss. 32, pp. 4663-4671
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases
Hui‐Lee Wong, Mao Hu, Cindy Ke Zhou, et al.
The Lancet (2022) Vol. 399, Iss. 10342, pp. 2191-2199
Open Access | Times Cited: 146
Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada
Sarah A. Buchan, Chi Yon Seo, Caitlin Johnson, et al.
JAMA Network Open (2022) Vol. 5, Iss. 6, pp. e2218505-e2218505
Open Access | Times Cited: 131
Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review
Jennifer Pillay, L. Gaudet, Aireen Wingert, et al.
BMJ (2022), pp. e069445-e069445
Open Access | Times Cited: 115
Myocarditis following COVID‐19 vaccine: incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective. A clinical consensus document supported by the Heart Failure Association of the European Society of Cardiology (ESC) and the ESC Working Group on Myocardial and Pericardial Diseases
Bettina Heidecker, Noa Dagan, Ran D. Balicer, et al.
European Journal of Heart Failure (2022) Vol. 24, Iss. 11, pp. 2000-2018
Open Access | Times Cited: 107
mRNA vaccines: The future of prevention of viral infections?
Piotr Rzymski, Agnieszka Szuster−Ciesielska, Tomasz Dzieciątkowski, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 2
Closed Access | Times Cited: 47
Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination
Kristin Goddard, Ned Lewis, Bruce Fireman, et al.
Vaccine (2022) Vol. 40, Iss. 35, pp. 5153-5159
Open Access | Times Cited: 49
Incidence and management of the main serious adverse events reported after COVID‐19 vaccination
Teresa Padilla‐Flores, Alicia Sampieri, Luis Vaca
Pharmacology Research & Perspectives (2024) Vol. 12, Iss. 3
Open Access | Times Cited: 9
COVID-19 Vaccine Safety Technical (VaST) Work Group: Enhancing vaccine safety monitoring during the pandemic
Lauri E. Markowitz, Robert Hopkins, Karen R. Broder, et al.
Vaccine (2024) Vol. 42, pp. 125549-125549
Open Access | Times Cited: 7
Cost-effectiveness Analysis of COVID-19 mRNA XBB.1.5 Fall 2023 Vaccination in the Netherlands
Florian Zeevat, Simon van der Pol, Tjalke A. Westra, et al.
Advances in Therapy (2025)
Open Access
Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance
Sharifa Nasreen, Andrew Calzavara, Sarah A. Buchan, et al.
Vaccine (2022) Vol. 40, Iss. 24, pp. 3305-3312
Open Access | Times Cited: 17
Near real-time surveillance of safety outcomes in US COVID-19 vaccine recipients aged 12 to 64 years
Patricia C. Lloyd, Mao Hu, Hui‐Lee Wong, et al.
Vaccine (2022) Vol. 40, Iss. 45, pp. 6481-6488
Open Access | Times Cited: 16
mRNA COVID-19 vaccine safety among children and adolescents: a Canadian National Vaccine Safety Network cohort study
Phyumar Soe, Otto G. Vanderkooi, Manish Sadarangani, et al.
The Lancet Regional Health - Americas (2024) Vol. 40, pp. 100949-100949
Open Access | Times Cited: 3
Cardiovascular safety of COVID-19 vaccines in real-world studies: a systematic review and meta-analysis
Yafei Chang, Guoli Lv, Chao Liu, et al.
Expert Review of Vaccines (2022) Vol. 22, Iss. 1, pp. 25-34
Open Access | Times Cited: 15
Myocarditis and Pericarditis Post-mRNA COVID-19 Vaccination: Insights from a Pharmacovigilance Perspective
Abdallah Alami, Paul J. Villeneuve, Paul J. Farrell, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 15, pp. 4971-4971
Open Access | Times Cited: 6
A narrative review of vaccine pharmacovigilance during mass vaccination campaigns: Focus on myocarditis and pericarditis after COVID‐19 mRNA vaccination
Pierre‐Philippe Piché‐Renaud, Shaun K. Morris, Karina A. Top
British Journal of Clinical Pharmacology (2022) Vol. 89, Iss. 3, pp. 967-981
Open Access | Times Cited: 10
Higher Troponin Levels on Admission are associated With Persistent Cardiac Magnetic Resonance Lesions in Children Developing Myocarditis After mRNA-Based COVID-19 Vaccination
Emma Concetta Manno, Donato Amodio, Nicola Cotugno, et al.
The Pediatric Infectious Disease Journal (2022) Vol. 42, Iss. 2, pp. 166-171
Open Access | Times Cited: 10
Protecting Children Against Omicron
Sophie E. Katz, Kathryn M. Edwards
JAMA (2022) Vol. 327, Iss. 22, pp. 2195-2195
Open Access | Times Cited: 8
Myopericarditis following COVID-19 vaccination in children: a systematic review and meta-analysis
Ashiley Annushri Thenpandiyan, Ryan Ruiyang Ling, Robert Grignani, et al.
Singapore Medical Journal (2024)
Open Access | Times Cited: 1
Vaccine Hesitancy and Associated Factors Amongst Health Professionals: A Scoping Review of the Published Literature
Antonios Christodoulakis, Izolde Bouloukaki, Antonia Aravantinou-Karlatou, et al.
Vaccines (2024) Vol. 12, Iss. 12, pp. 1411-1411
Open Access | Times Cited: 1
Background incidence rates of selected adverse events of special interest (AESI) to monitor the safety of COVID-19 vaccines
Alexis Pillsbury, Anastasia Phillips, Lucy Deng, et al.
Vaccine (2023) Vol. 41, Iss. 22, pp. 3422-3428
Open Access | Times Cited: 4
Cardiopulmonary complications following COVID-19 vaccinations: a systematic review and meta-analysis
Bnar J. Hama Amin, Dana H. Mohammed Saeed, Hadi Mohammed Abdullah, et al.
Barw Medical Journal (2023)
Open Access | Times Cited: 2
Thrombosis with thrombocytopenia syndrome (TTS) following adenovirus vector COVID-19 vaccination in Canada
Theresa D. Procter, Hitoshi Ogasawara, Sarah Spruin, et al.
Vaccine (2023) Vol. 41, Iss. 46, pp. 6802-6809
Open Access | Times Cited: 2
Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance
Sharifa Nasreen, Andrew Calzavara, Sarah A. Buchan, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 3
Miocardite associada à vacinação e infecção por Covid-19: uma análise detalhada da incidência e considerações clínicas
Bruna Loureiro Leoncio Blanck, Kélly Testa Santorio, Ludmyla Araujo Freitas, et al.
Cuadernos de Educación y Desarrollo (2024) Vol. 16, Iss. 2 Edição Especial
Open Access
Occurrence of Myopericarditis Following COVID-19 Vaccination Among Adults in the Eastern Region, Saudi Arabia: A Multicenter Study
Eidan Al Zahrani, Salah H. Elsafi, Rawan Alkharraz, et al.
International Journal of General Medicine (2024) Vol. Volume 17, pp. 3231-3237
Open Access
Page 1 - Next Page

Scroll to top